[go: up one dir, main page]

SE9903609D0 - Novel compounds I - Google Patents

Novel compounds I

Info

Publication number
SE9903609D0
SE9903609D0 SE9903609A SE9903609A SE9903609D0 SE 9903609 D0 SE9903609 D0 SE 9903609D0 SE 9903609 A SE9903609 A SE 9903609A SE 9903609 A SE9903609 A SE 9903609A SE 9903609 D0 SE9903609 D0 SE 9903609D0
Authority
SE
Sweden
Prior art keywords
selective inhibitor
atpase
vacuolar
present
novel compounds
Prior art date
Application number
SE9903609A
Other languages
Swedish (sv)
Inventor
Margareta Hersloef
Henrik Soerensen
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9903609A priority Critical patent/SE9903609D0/en
Publication of SE9903609D0 publication Critical patent/SE9903609D0/en
Priority to PCT/SE2000/001857 priority patent/WO2001025207A1/en
Priority to JP2001528153A priority patent/JP2003511368A/en
Priority to EP00970370A priority patent/EP1222170A1/en
Priority to CA002385244A priority patent/CA2385244A1/en
Priority to AU79762/00A priority patent/AU7976200A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)

Abstract

The present invention relates to a selective inhibitor of mammalian osteoclast cell activity, processes for its preparation and pharmaceutical compositions comprising the same as well as methods of treatment, where said selective inhibitor is administered to a human or animal patient. Said selective inhibitor has been found to inhibit vacuolar H<+>-ATPase, such as vacuolar H<->ATPase in osteoclast cells, whereby it is therapeutically efficient against physiological disorders involving bone resorption. In an embodiment of the present invention, said selective inhibitor comprises a nicotinonitrile compound with general formula (I).
SE9903609A 1999-10-06 1999-10-06 Novel compounds I SE9903609D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE9903609A SE9903609D0 (en) 1999-10-06 1999-10-06 Novel compounds I
PCT/SE2000/001857 WO2001025207A1 (en) 1999-10-06 2000-09-26 Novel nicotinonitrile compounds
JP2001528153A JP2003511368A (en) 1999-10-06 2000-09-26 New nicotinonitrile compounds
EP00970370A EP1222170A1 (en) 1999-10-06 2000-09-26 Novel nicotinonitrile compounds
CA002385244A CA2385244A1 (en) 1999-10-06 2000-09-26 Novel nicotinonitrile compounds
AU79762/00A AU7976200A (en) 1999-10-06 2000-09-26 Novel nicotinonitrile compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903609A SE9903609D0 (en) 1999-10-06 1999-10-06 Novel compounds I

Publications (1)

Publication Number Publication Date
SE9903609D0 true SE9903609D0 (en) 1999-10-06

Family

ID=20417269

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903609A SE9903609D0 (en) 1999-10-06 1999-10-06 Novel compounds I

Country Status (6)

Country Link
EP (1) EP1222170A1 (en)
JP (1) JP2003511368A (en)
AU (1) AU7976200A (en)
CA (1) CA2385244A1 (en)
SE (1) SE9903609D0 (en)
WO (1) WO2001025207A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2331418C2 (en) * 2006-05-24 2008-08-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) Isonicotinoylhydrazide phthalate as antidiabetic agent
EP3043646A4 (en) * 2013-08-29 2017-05-17 D. Tyler Mcquade Methods of making 2-halonicotinonitriles

Also Published As

Publication number Publication date
JP2003511368A (en) 2003-03-25
AU7976200A (en) 2001-05-10
CA2385244A1 (en) 2001-04-12
EP1222170A1 (en) 2002-07-17
WO2001025207A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
CY1107850T1 (en) THIADIAZYLOPIPERAZINE PRODUCT WITH USE IN APTROPIC OR IN ACTION AGAINST ALGUES
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
DE69912313D1 (en) COLCHINOL DERIVATIVES AS VESSEL-DAMAGING AGENTS
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
BR0012450A (en) Substituted benzimidazoles
WO2001039759A3 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
CY1108932T1 (en) Compounds 4- (heterocyclyl) -benzenesulfoximine for the therapeutic treatment of inflammatory diseases
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
NO20005912L (en) Sulfonyl acid or sulfonylamino-N- (heteroaralkyl) - azaheterocyclylamide compounds
ATE366107T1 (en) USE OF SULFODEHYDROABIETIC ACID TO TREAT INFLAMMATORY BOWEL DISEASE
DE60215313D1 (en) INDOIND DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS
SE9903611D0 (en) Novel compounds III
DK1115697T3 (en) Unsaturated hydroxymic acid derivatives as PARP inhibitors
SE0203820D0 (en) chemical compounds
SE0203828D0 (en) Chemical compounds
SE9903609D0 (en) Novel compounds I
SE9903610D0 (en) Novel compounds II
ATE286395T1 (en) ANTITHRBOTIC AGENTS
AU2001266019A1 (en) 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
AU2003216965A1 (en) Compounds, particularly of urea derivatives or ester derivatives of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases
EA200501591A1 (en) PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MUSCULAR SPASTICITY AND / OR PAIN
TW200508229A (en) Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
GEP20074194B (en) Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid
DE60318459D1 (en) NEW CONNECTIONS
UA54880C2 (en) (s)-2-amino-5-guanidinopentanoic acid (s)-2-aminoglutarate (l-arginine l-glutamate) possessing hepatoprotecting, hypoammoniemic, and detoxifying activity, method for its synthesis and pharmaceutical composition containing this substance